- Verona Pharma said first patients have been dosed in a Phase IIa combination study to evaluate the addition of RPL554 to standard reliever medications for chronic obstructive pulmonary disease (COPD).

RPL554 is a novel inhaled PDE3/PDE4 inhibitor with anti-inflammatory as well as bronchodilatory properties, currently in development as a nebulised treatment for acute exacerbations in COPD patients in a hospital or home-care setting. The nebulised bronchodilator market was worth approximately $1 billion in 2014 in the US.

The primary objective of this study is to evaluate whether RPL554 has an additive bronchodilator effect in COPD patients, when administered in addition to standard of care bronchodilators.

Story provided by